TSHA – taysha gene therapies, inc. (US:NASDAQ)
Stock Stats
News
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $7.00 price target on the stock.
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know [Yahoo! Finance]
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome [Yahoo! Finance]
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $7.00 price target on the stock.
Form DEFA14A Taysha Gene Therapies,
Form ARS Taysha Gene Therapies, For: Dec 31
Form DEF 14A Taysha Gene Therapies, For: May 29
Form S-8 Taysha Gene Therapies,
Form 8-K Taysha Gene Therapies, For: Mar 19
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.